(Q40354615)

19 September 2017

title

Flow cytometry: a new approach for the molecular profiling of breast cancer (English)

1 reference

19 September 2017

1 reference

Lostumbo A

1

1 reference

19 September 2017

Mehta D

series ordinal

2

1 reference

19 September 2017

Setty S

series ordinal

3

1 reference

19 September 2017

Nunez R

series ordinal

4

1 reference

19 September 2017

publication date

3 November 2005

1 reference

Experimental and Molecular Pathology

19 September 2017

published in

1 reference

19 September 2017

volume

80

1 reference

19 September 2017

issue

1

1 reference

19 September 2017

page(s)

46-53

1 reference

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Tyrosine kinase inhibitors-ZD1839 (Iressa).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Biomolecular prognostic factors in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

The EGF receptor system as a target for antitumor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Molecular prognostic factors for breast cancer metastasis and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

EGF-dependent cell cycle progression is controlled by density-dependent regulation of Akt activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Docetaxel/trastuzumab combination therapy for the treatment of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Epidermal growth factor-related peptides and their receptors in human malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Cytoplasmic p120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

The long term prognostic significance of c-erbB-2 in primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

The epidermal growth factor receptor and its inhibition in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Measurement of markers for breast cancer in a model system using laser scanning cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

Rho-stimulated contractility contributes to the fibroblastic phenotype of Ras-transformed epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2005.09.007

10.1016/J.YEXMP.2005.09.007

7 January 2021

Identifiers

DOI

1 reference

release_wpiy7nbrubh47psjsfzzn2o4ly

19 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wpiy7nbrubh47psjsfzzn2o4ly

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference